|Articles|March 19, 2020
Episode 52: Cannabinoids
Author(s)Christen Harm, Elaine Quilici
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
Advertisement
Yuval Cohen, CEO of Corbus Pharmaceuticals, talks about cannabinoids, the differences between natural and synthetic products, and how biotechs and pharma are using them to treat disease today.
You can listen and/or download the episode on SoundCloud, or directly through iTunes, GooglePlay, Stitcher, and Overcast.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
What Pharma Marketers Need to Know About Recent Gartner Predictions About AI and What It Means to Them
2
FDA Approves Icotyde as Treatment of Moderate-to-Severe Plaque Psoriasis in Adults and Adolescents
3
What Governance Resets Should Pharma Companies Take in Response to AI?
4
Conflict in Middle East Disrupts Pharma Drug Supplies: Report
5